logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings | Journal Article / Review | MSF Science Portal
Journal Article
|Review

Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings

Ford NP, Lee JS, Andrieux-Meyer I, Calmy A
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
Integrase inhibitors represent an important new class of antiretroviral drugs. Elvitegravir, the second available integrase inhibitor to be submitted for regulatory approval appears to be a promising once-daily agent when combined with other antiretroviral drugs. Elvitegravir has demonstrated good efficacy and safety, with minimal side effects and no specific requirements in terms of laboratory monitoring. In addition, elvitegravir is available as a fixed-dose combination. However, the drug requires boosting and this leads to a number of drug-drug interactions and necessary dose adjustment when dosing with certain drugs, including dose reduction in the presence of atazanavir, lopinavir, rifabutin, and ketoconazole, and dose increase for ethinyl estradiol when co-administered with boosted elvitegravir. The main advantage of elvitegravir lies in its potential to be administered as a once-daily, single pill. Limitations include dose adjustment requirements, a relatively low genetic barrier to resistance, high price, and lack of data for use in children. Clinical trials addressing specific challenges encountered in resources-limited settings should be encouraged.

Countries

none

Subject Area

HIV/AIDS

Languages

English
DOI
10.1016/S1473-3099(11)70354-1
Published Date
11 Jan 2012
PubMed ID
22347806
Journal
HIV/AIDS - Research and Palliative Care
Volume | Issue | Pages
Volume 12
Issue Date
2012-01-01
Dimensions Badge